Thelansis’s "Allan-Herndon-Dudley Syndrome (AHDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Allan-Herndon-Dudley Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Allan-Herndon-Dudley syndrome (AHDS), also called MCT8 deficiency, is a rare X-linked disorder caused by pathogenic variants in SLC16A2, which encodes the thyroid hormone transporter MCT8. Impaired transport limits thyroid hormone entry into the brain while exposing peripheral tissues to excess thyroid hormone. Affected boys typically develop severe motor and cognitive impairment, hypotonia, dystonia or spasticity, poor head control, feeding difficulties, and delayed milestones; severity varies. Care includes nutritional and respiratory support, physiotherapy, management of movement symptoms, and cardiac and thyroid monitoring. In September 2026, the FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in adults and children with MCT8 deficiency. Studies showed lower thyroid-hormone levels and improved heart rate and blood pressure. Its effect on established neurological impairment remains uncertain. Gene therapy remains investigational.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Allan-Herndon-Dudley Syndrome (AHDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Allan-Herndon-Dudley Syndrome (AHDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.